Details
Category: Volume 06 Issue 06 June 2018
Hits: 1369

Title: Correlation of levels of Prostate Specific Antigen with Histopathological findings in patient diagnosed with prostate adenocarcinoma: A study from Central India

Authors: Dr Anshu Hotani, Dr Neha Ramsinghani

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i6.33

Abstract

Introduction: Prostate cancer is the second most common malignant tumor in western males and anatomically involves the prostate peripheral zone.  It is the most common type of cancer in men. To prevent an equal rise in mortality, early detection of prostate cancer will become essential, as will the detection of premalignant lesions such as prostatic intraepithelial neoplasia. Prostate cancer can only be diagnosed by thorough histopathological examination of prostatic tissue along with serum PSA levels estimation.

Material and Methods: A Cross sectional study done over a period of 18months, was carried out on 150 prostate specimens. The specimens were examined for various prostatic pathologies by doing histopathological examination & their serum total PSA values were correlated. Patients diagnosed as prostate adenocarcinoma were included. On the contrary inadequate biopsy material cases, autolyzed specimen and patients younger than 40 years were not included.

Results: Amongst 38 (25.3%) adenocarcinoma cases, 15 cases (10.0%) were well differentiated, 08 cases (5.3%) were intermediate grade, 03 cases (2.0%) were moderately to poorly differentiated and 12 cases (8.0%) were poorly differentiated.

Discussion: The percentage of occurrence of occult carcinoma has significantly decreased over the years due to advanced investigative procedures like TRUS, serum PSA level estimation etc.

Conclusion: A combination of staging, grading and follow- up study is required to obtain best predictive values.

Keywords: PSA, Prostate cancer, Adenocarcinoma prostate.

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians. 2013;63(1):11-30.
  2. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Eds.). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon 2004. 158, 193-195, 169-172.
  3. Barry MJ, Fowler FJ, Jr, Bin L, Pitts JC, 3rd, Harris CJ, Mulley AG., Jr The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol. 1997;157:10–4. 
  4. Bosch JL, Hop WC, Kirkels WJ, Schröder FH. Natural history of benign prostatic hyperplasia: Appropriate case definition and estimation of its prevalence in the community. 1995;46:34–40
  5. Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: Prediction of future prostate volume in individual men. 2007;67:1816–24. 
  6. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: Results from the Baltimore Longitudinal Study of Aging.J Urol. 2009;182:1458–62. 
  7. Centers for Disease Control and Prevention (CDC). Trends in aging-United States and worldwide.MMWR Morb Mortal Wkly Rep. 2003;52(6):101–4. 
  8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (March 2008). "Cancer Statistics,2008". CA Cancer J Clin 58 (2): 71–96.doi:3322/ CA.2007. 0010. PMID18287387.
  9. Liwei Huang, Yongbing Pu, Wen Yang Hu, Lynn Birch, Douglas Luccio-Camelo, Terry Yamaguchi, Gail S Prins The role of Wnt5a in prostate gland development.Dev. Biol.: 2009, 328(2);188-99 PMID: 19389372
  10. Jump up Chad M Vezina, Tien-Min Lin, Richard E Peterson AHR signaling in prostate growth, morphogenesis, and disease. Biochem. Pharmacol.: 2009, 77(4);566-76PMID: 18977204.
  11. Junn D. Chavez, Jr. Basic Immunohistochemistry HTL (ASCP) QIHC Quality Control Laboratory, Lab Vision Corporation 2009
  12. Bancrofft John D. Theory and practice of histological techniques 5th edition.
  13. Jasani JH, Patel HB, Gheewala B, Vaishnani HV, Bhuva K, Sancheti S, Patel A, Tandon R. IJBAR. 2012; 03: 268-272.
  14. Haroun AA, Hadidy AS, Awwad ZM, Nimri CF, Mahafza WS, Tarawneh ES. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer. Saudi J Kidney Dis Transpl. 2011 Mar; 22(2):2917.
  15. Pacelli A, Bostwick DG. Clinical significance of high grade prostatic intra epithelial neoplasia in transurethral resection specimens. Urology.1997; 50:355– 359.
  16. Nishant D. Patel et al. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014 Apr-Jun; 30(2): 170-176.
  17. Mwakyoma HA. The Prevalence of High Grade Prostatic Intraepithelial Neoplasia in Prostatic Biopsies Diagnosed As benign Prostatic Hyperplasia at Muhimbili National Hospital, Dar es Salaam. Tanzania Medical Journal. 2008; 23 (1): 1-4.
  18. David G Bostwick1 et al. High-grade prostatic intraepithelial neoplasia. Modern Pathology (2004) 17, 360–379, advance online publication, 23 January 2004
  19. Skjorten FJ, Berner A, Harvei S, Robsahm TE, Tretli S. Prostatic intraepithelial neoplasia in surgical Relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate. Cancer. 1997; 79: 1172-1179
  20. Rekhi B, Jaswal TS, Arora B. Premalignant lesions of prostate and their association with nodular hyperplasia and carcinoma prostate. Indian J Cancer. 41: 60-65.
  21. Shimada H, Misugi K, Sasaki Y, Iizuka A, Nishihira H. Carcinoma of the prostate in childhood and adolescence. Report of a case and review of the literature. Cancer. 1980; 46: 2534 – 42.
  22. Xie LP, Qin J, Zheng XY, Shen HF, Chen ZD, Cai SL, Zhang ZG, Ding W, Ren GP, Wang LJ, Yu XR. Age and pathological features of 481 prostate cancer patients. Zhonghua Nan Ke Xue. 2005 Jun; 11(6):428-30.
  23. David C. Miller et al. Prostate Carcinoma Presentation, Diagnosis, and Staging. An Update from the National Cancer Data Base. 2003 American Cancer Society DOI10.1002/cncr.11635 June 23, 2003.
  24. Lyn NNK, Collins GN, Alex AK, Brown SCW, Brooman PJ, O'reilly PH. Prostate specific antigen parameters in clinical practice. The prostate Journal. 2(4): 205-210.
  25. Mwakyoma HA, Mabandi JL. Correlation of Gleason's score and pretreatment prostate specific antigen in patients. Professional Med J Jun 2010; 17(2): 235-240.
  26. Divrik RT, Erog A, Sahin A, Zorlu F, Ozen H. Increasing the number of biopsies increases the concordance of Gleason‘s score's of needle biopsies and prostatectomy specimens. Urol Oncol semin. 2007; 25: 376-82.
  27. Kshitij A. jyoti sapre, A.S.Agnihotri et al: Utility of prostate specific antigen in different prostatic lesion: Pathology and laboratory medicine; Jun 2011; Vol 3 issue 1 : 18-23.
  28. Brawer MK, Lange PH, Prostate-specific antigen and premalignant change: implications for early detection. CA 1989; 39: 361-75.
  29. H A Mwaakyoma et al. Correlation of Gleason”s score and pretreatment prostate specific antigen in patients. Professssional Med J Jun 2010; 17(2) : 235-240.
  30. Sladana Zivkovic et al: Correlation prostate specific antigen and histopathologicl difference of prostate carcinoma; arch Oncol 2004;12(3) 148-51.

Corresponding Author

Dr Neha Ramsinghani

Senior Resident, Netaji Subash Medical College, Jabalpur, MP India